From a practical perspective, this means that if retatrutide is eventually approved for use in obesity and diabetes, most patients can expect side effects to be manageable and temporary
The second matters more: the rare but serious risk of a prolonged erection
Anecdotal research protocols use approximately 400 mcg administered intranasally once daily, typically in the morning
In most cases, adults may qualify for GLP-1 weight loss medications with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, prediabetes, high cholesterol, sleep apnea, or cardiovascular disease
If prescribed, medication is fulfilled by a licensed U.S
The move underscores CenterWell Pharmacys focus on building closer connections with employers to enhance health care access and affordability